Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-03

Clinical Trial Update: Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating bevacizumab for severe retinopathy of prematurity has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)

Snippet

Sponsor: Jaeb Center for Health Research | Conditions: Retinopathy of Prematurity | Phase 1 | Status: COMPLETED | Results posted: 2022-11-03